Teva (TEVA) Enters a New $700 Million Acquisition Deal

On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive statement to get Emalex Biosciences. The transaction involves $700 cardinal successful cash, positive up to $200 cardinal successful milestone payments and royalties. Through the acquisition, the institution gains entree to ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. Following affirmative Phase 3 results, ecopipam awaits an NDA successful the 2nd fractional of 2026. The transaction is anticipated to adjacent by Q3 2026, with Teva Pharmaceutical Industries Limited (NYSE:TEVA) maintaining its 2027 fiscal targets contempt the near-term investment.

Separately, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Q1 2026 net results connected April 29, 2026, highlighting a 2% summation successful gross year-over-year to astir $4 cardinal successful USD. The institution attributes the summation to its innovative portfolio maturation and disciplined execution, contempt facing headwinds successful lenalidomide capsules. The company’s non-GAAP EPS of $0.53 surpassed the statement estimation of $0.48 – $0.50.

Druckenmiller built a multi-quarter presumption connected the banal earlier trimming successful Q4 2025, portion Cramer reversed his long-held skepticism and hosted the CEO successful January 2026, praising a genuine turnaround.

The institution brought successful a caller leader, Richard Francis, astatine the opening of 2023, and the banal hasn’t looked backmost since, astir 400% summation from its 2022 lows.

Founded successful 1901, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is simply a starring innovative biopharmaceutical company. The Israel-based institution focuses connected developing, manufacturing, marketing, and distributing generic and different medicines and biopharmaceutical products.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 New Contenders for S&P 500 Index and Harvard University Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey connected Google News.